izalontamab brengitecan   Click here for help

GtoPdb Ligand ID: 14566

Synonyms: BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
Approved drug
izalontamab brengitecan is an approved drug
Compound class: Antibody
Comment: Izalontamab brengitecan (BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) that is designed to deliver the camptothecin derived topoisomerase I inhibitor Ed-04 payload to tumour cells that express EGFR and HER3 receptor tyrosine kinases. The drug carries of eight toxin molecules per antibody (SI-B001) molecule [7,9]. Peptide sequences for the heavy and light chains of the parental antibody (obtained from the INN record) are claimed in patent US10919977, specifically for the clone named SI-1X6.4 [3].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Izalontamab brengitecan (BL-B01D1) was evaluated as a clinical candidate for the treatment of heavily pre-treated solid tumours (of epithelial origin), including EGFR-mutated NSCLCs, esophageal squamous cell carcinoma (ESCC) [5], ovarian cancer, and urothelial carcinoma [1]. It was first approved for clinical use by China's NMPA in June 2026, to treat recurrent or metastatic nasopharyngeal carcinoma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07502300 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) Phase 3 Interventional Sichuan Baili Pharmaceutical Co., Ltd.
NCT07582315 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) Phase 3 Interventional Sichuan Baili Pharmaceutical Co., Ltd.
NCT07640789 A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) Phase 3 Interventional Sichuan Baili Pharmaceutical Co., Ltd.
NCT07648914 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Phase 3 Interventional Sichuan Baili Pharmaceutical Co., Ltd.
NCT05194982 A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor Phase 1 Interventional Sichuan Baili Pharmaceutical Co., Ltd. 4,6
NCT05880706 A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Phase 2 Interventional Sichuan Baili Pharmaceutical Co., Ltd. 4
NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) Phase 3 Interventional Sichuan Baili Pharmaceutical Co., Ltd. Objective response rate, median duration of response and median progression-free survival were all significantly increased by BL-B01D1 treatment compared to chemotherapy. 10